Genome sequences of two clinical Escherichia coli isolates harboring the novel colistin-resistance gene variants mcr-1.26 and mcr-1.27

Table 2 Antibiotic susceptibilities of mcr-1-like positive donor strains and transconjugants (MICs in mg/L)

Strain no.	AMP	CTX	CAZ	FOX^b	GEN	AMK	STR^b	CMP	TET^b	NAL^b	CIP	MER	TRS	COL
803/18 E. coli (B1, ST155)^a	> 16	≤ 1	≤ 2	4	1	≤ 2	> 64	8	> 8	> 32	0.5	≤ 0.063	> 128	4
803/18 Tc1 E. coli J53 Azi^r (A, ST10)^a	> 16	≤ 1	≤ 2	8	4	16	> 64	≤ 4	1	16	≤ 0.063	≤ 0.063	≤ 4	2
844/18 E. coli (D, ST69)^a	> 16	≤ 1	≤ 2	8	2	4	16	> 32	>8	> 32	0.5	≤ 0.063	> 128	4
844/18 Tc1 E. coli J53 Azi^r (A, ST10)^a	4	≤ 1	≤ 2	4	≤ 0.5	≤ 2	≤ 4	32	>8	8	≤ 0.063	0.125	> 128	2
E. coli J53 Azi^r (A, ST10)^a recipient	4	≤ 1	≤ 2	2	≤ 0.5	≤ 2	≤ 4	8	1	8	≤ 0.063	≤ 0.063	≤ 4	0.125

Antibiotic susceptibility testing was performed by broth microdilution with MIC interpretation of minimum inhibitory concentrations (MICs) according recommendations of the European Committee on Antimicrobial Susceptibility testing (EUCAST v 10.0). Tc1, transconjugants; ^aE. coli phylogentic group determined by PCR according Clermont et al. [8], and multilocus sequence type (ST) according to the MLST scheme of Achtmann (Wirth et al. [12]). ^bFor these substance only epidemiological cut-off values (ECOFFs) are available to separates microorganisms without (wild type) and with acquired resistance mechanisms (non-wild type) to the agent in question (http://www.eucast.org)
AMP ampicillin, CTX cefotaxime, CAZ ceftazidime, FOX cefoxitin, GEN gentamicin, AMK amikacin, STR streptomycin, NAL nalidixic acid, CMP chloramphenicol, TET tetracycline, CIP ciprofloxacin, MER meropenem, TRS trimethoprim/sulfamethoxazole, COL colistin

ISSN: 1757-4749